In this session, IBD experts will share their knowledge and experiences. The session will kick off with a keynote address by Dr. Gil Y. Melmed from Cedars-Sinai Medical Center, USA, focusing on the tailored management of difficult-to-treat IBD. Following the keynote, our session will explore the latest updates on both potent IBD therapeutic agents, “old and new biologics,” as well as “small molecules” in the treatment of IBD.

This session will explore cutting-edge issues in IBD. Our session aims to address several hot IBD topics, ranging from cutting-edge strategies for early detection and prevention of IBD to challenging clinical issues including managing bowel strictures in Crohn’s disease and providing comprehensive care for pregnant women with IBD and their children. Join us as we explore and discuss the latest developments in IBD, navigating hot issues with a focus on innovation and practical insights.

Emerging biologics and small-molecule drugs have changed the clinical status quo of inflammatory bowel disease (IBD). However, in many cases, current treatments remain at a standstill in terms of response and remission. Therefore, there is a great need to make the best use of therapeutic options. This comprehensive session will provide up-to-date knowledge regarding optimal management and selection of biologics and small molecules in the IBD fields. Esteemed experts in the IBD field will lead in-depth discussions on general strategies for managing IBD and integrating insight into biologics and small molecules. Significantly, gem lectures by notable speakers are scheduled for this session. Professor Byong Duk Ye is an associate editor of Inflammatory Bowel Disease and a leading researcher in IBD treatment at Asan Medical Center. Another speaker, Professor Parambir S Dulia, is a crucial researcher on biologics and small molecule administration in IBD patients at Northwestern University. In addition, honorable researchers from various fields will share their perspectives in engaging presentations and discussions on the latest advances in the field.

- Prize: USD 200
- Number of winners: 50 Awardees
- Eligibility

• Pre-registration by March 31 (Sun.), 2024 is required.
• Participants of foreign affiliations who are not presenting authors can be candidates for the travel grants. Specifically, foreign participants who did not submit abstracts OR who are corresponding authors or co-authors are eligible.
• Participants from countries listed on the have priority, however, this qualification is only a priority, not mandatory.

IMKASID 2024 Pre-Registration is ongoing! We implore you to register now to take advantage of pre-registration rates and then join the IMKASID 2024!
Some sessions require pre-registration, so don't miss this opportunity.